The Role of PCSK9 Inhibitors: Opportunities for Pharmacists to Optimize Care

This activity was originally broadcast live as a satellite symposium held in conjunction with APhA2022.

Program Description

Hyperlipidemia is a significant contributor to atherosclerotic cardiovascular disease. It is estimated that fewer than 50% of patients with high cholesterol receive treatment; furthermore, fewer than 35% of patients receiving treatment achieve adequate cholesterol levels with therapy. Statins are used most frequently as lipid-lowering therapy, but their use is associated with poor adherence and adverse effects that contribute to patients discontinuing therapy. Pharmacists have an important role in identifying patients who may benefit from the use of PCSK9 inhibitors, for example, individuals who do not achieve appropriate cholesterol levels with statin monotherapy. This program will familiarize pharmacists with the most recent guideline updates to provide a patient-centered approach to hyperlipidemia management with a focus on the role of PCSK9 inhibitors. Real-world data analyzing safety and cost efficacy of PCSK9 inhibitors will also be presented to equip pharmacists in making clinical interventions to ensure the optimal management of patients with hyperlipidemia.

Target Audience: Retail pharmacists

Type of Activity: Application
Release date: April 4, 2022
Expiration date: April 4, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the pathogenesis, incidence, risk factors, and current standards of care for the treatment of hyperlipidemia.
• Explain the most current hyperlipidemia management guidelines from the American Heart Association and the American College of Cardiology.
• Investigate the efficacy and safety data associated with the use of PCSK9 inhibitors and their clinical benefits in the treatment of hyperlipidemia including real-world data.
• Explore the role of the pharmacist in identifying and educating patients who may be ideal candidates for PCSK9 inhibitors for the treatment of hyperlipidemia.